When to Use Aspirin for Secondary Prevention
Low-dose aspirin (75-162 mg daily) is recommended for all patients with established atherosclerotic cardiovascular disease—including prior myocardial infarction, ischemic stroke, transient ischemic attack, or peripheral arterial disease—unless contraindicated. 1
Specific Clinical Scenarios
Coronary Artery Disease (Prior MI or Stable Angina)
- Aspirin 75-162 mg daily should be initiated and continued indefinitely in all patients with coronary artery disease unless contraindicated 1
- For patients intolerant or allergic to aspirin, clopidogrel 75 mg daily serves as an alternative 1
- After acute coronary syndrome or PCI with stent placement, dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) is indicated for at least 12 months, followed by aspirin monotherapy 1
- Meta-analysis demonstrates that low-dose aspirin reduces cardiovascular events by 21%, nonfatal MI by 26%, and all-cause mortality by 13% in stable cardiovascular disease 2
Cerebrovascular Disease (Prior Stroke or TIA)
For symptomatic carotid stenosis or recent ischemic stroke/TIA:
- Dual antiplatelet therapy with aspirin and clopidogrel 75 mg is recommended for the first 21 days, followed by single antiplatelet therapy long-term 3
- This 21-day window is critical—the POINT trial showed that benefits occur predominantly within the first 21 days (hazard ratio 0.65 for major ischemic events), while hemorrhage risk remains constant throughout 90 days 4, 5
- After 21 days, continue with either aspirin alone (75-325 mg daily), clopidogrel alone (75 mg daily), or aspirin plus extended-release dipyridamole (25 mg/200 mg twice daily) 1
For asymptomatic carotid stenosis >50%:
- Long-term antiplatelet therapy (commonly low-dose aspirin) should be considered if bleeding risk is low 3
Peripheral Arterial Disease
- Aspirin 75-325 mg daily or clopidogrel 75 mg daily should be initiated and continued in patients with symptomatic atherosclerotic peripheral artery disease of the lower extremity 1
- Evidence suggests clopidogrel may be preferred over aspirin specifically in peripheral arterial disease patients based on superior efficacy in this subgroup 6, 7
Dosing Considerations
- Daily doses of 75-162 mg are as effective as higher doses for long-term secondary prevention 1, 8
- During acute MI, a loading dose of 160-325 mg may be given initially, followed by 75-150 mg daily 8
- Doses below 75 mg daily have uncertain efficacy 8
- Doses exceeding 325 mg daily increase side effects without additional benefit 8, 9
Important Caveats
Bleeding risk considerations:
- Aspirin increases major bleeding risk approximately 2-fold (odds ratio 2.2) 2
- However, treating 1000 patients for 33 months prevents 33 cardiovascular events while causing only 9 major bleeding events—a favorable benefit-to-risk ratio 2
- Aspirin is preferred over warfarin for atherosclerosis unless there is a compelling indication for anticoagulation (atrial fibrillation, prosthetic valve, left ventricular thrombus) 1
When warfarin is required:
- If anticoagulation is necessary, warfarin should be combined with low-dose aspirin 75-81 mg daily 1
- The combination of warfarin with aspirin and/or clopidogrel increases bleeding risk 1
Pregnancy considerations:
- Aspirin should be avoided during the last 3 months of pregnancy unless specifically directed by a physician, as it may cause problems in the unborn child or complications during delivery 10
Key Pitfall to Avoid
The most common error is continuing dual antiplatelet therapy beyond 21 days in stroke/TIA patients when not indicated post-PCI or ACS. The POINT trial clearly demonstrated that hemorrhage risk continues while ischemic benefit diminishes after 21 days 4, 5. After this critical window, transition to monotherapy unless there are other compelling indications for dual therapy.